Information Provided By: 
Fly News Breaks for May 24, 2019
FATE
May 24, 2019 | 07:22 EDT
Citi analyst Yigal Nochomovitz assumed coverage of Fate Therapeutics with a Buy rating and raised his price target for the shares to $26 from $20. Fate's iPSC-based platform to produce cancer-killing cells could be game changing versus current autologous cell therapies, Nochomovitz tells investors in a research note.
News For FATE From the Last 2 Days
FATE
Apr 18, 2024 | 17:52 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSMetropolitan... To see the rest of the story go to thefly.com. See Story Here
